News | January 18, 2026
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Subscribe To Our Newsletter & Stay Updated
